Cargando…

Deep phenotyping for precision medicine in Parkinson's disease

A major challenge in medical genomics is to understand why individuals with the same disorder have different clinical symptoms and why those who carry the same mutation may be affected by different disorders. In every complex disorder, identifying the contribution of different genetic and non-geneti...

Descripción completa

Detalles Bibliográficos
Autores principales: Schalkamp, Ann-Kathrin, Rahman, Nabila, Monzón-Sandoval, Jimena, Sandor, Cynthia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178512/
https://www.ncbi.nlm.nih.gov/pubmed/35647913
http://dx.doi.org/10.1242/dmm.049376
_version_ 1784723075583967232
author Schalkamp, Ann-Kathrin
Rahman, Nabila
Monzón-Sandoval, Jimena
Sandor, Cynthia
author_facet Schalkamp, Ann-Kathrin
Rahman, Nabila
Monzón-Sandoval, Jimena
Sandor, Cynthia
author_sort Schalkamp, Ann-Kathrin
collection PubMed
description A major challenge in medical genomics is to understand why individuals with the same disorder have different clinical symptoms and why those who carry the same mutation may be affected by different disorders. In every complex disorder, identifying the contribution of different genetic and non-genetic risk factors is a key obstacle to understanding disease mechanisms. Genetic studies rely on precise phenotypes and are unable to uncover the genetic contributions to a disorder when phenotypes are imprecise. To address this challenge, deeply phenotyped cohorts have been developed for which detailed, fine-grained data have been collected. These cohorts help us to investigate the underlying biological pathways and risk factors to identify treatment targets, and thus to advance precision medicine. The neurodegenerative disorder Parkinson's disease has a diverse phenotypical presentation and modest heritability, and its underlying disease mechanisms are still being debated. As such, considerable efforts have been made to develop deeply phenotyped cohorts for this disorder. Here, we focus on Parkinson's disease and explore how deep phenotyping can help address the challenges raised by genetic and phenotypic heterogeneity. We also discuss recent methods for data collection and computation, as well as methodological challenges that have to be overcome.
format Online
Article
Text
id pubmed-9178512
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Company of Biologists Ltd
record_format MEDLINE/PubMed
spelling pubmed-91785122022-06-09 Deep phenotyping for precision medicine in Parkinson's disease Schalkamp, Ann-Kathrin Rahman, Nabila Monzón-Sandoval, Jimena Sandor, Cynthia Dis Model Mech Review A major challenge in medical genomics is to understand why individuals with the same disorder have different clinical symptoms and why those who carry the same mutation may be affected by different disorders. In every complex disorder, identifying the contribution of different genetic and non-genetic risk factors is a key obstacle to understanding disease mechanisms. Genetic studies rely on precise phenotypes and are unable to uncover the genetic contributions to a disorder when phenotypes are imprecise. To address this challenge, deeply phenotyped cohorts have been developed for which detailed, fine-grained data have been collected. These cohorts help us to investigate the underlying biological pathways and risk factors to identify treatment targets, and thus to advance precision medicine. The neurodegenerative disorder Parkinson's disease has a diverse phenotypical presentation and modest heritability, and its underlying disease mechanisms are still being debated. As such, considerable efforts have been made to develop deeply phenotyped cohorts for this disorder. Here, we focus on Parkinson's disease and explore how deep phenotyping can help address the challenges raised by genetic and phenotypic heterogeneity. We also discuss recent methods for data collection and computation, as well as methodological challenges that have to be overcome. The Company of Biologists Ltd 2022-06-01 /pmc/articles/PMC9178512/ /pubmed/35647913 http://dx.doi.org/10.1242/dmm.049376 Text en © 2022. Published by The Company of Biologists Ltd https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
spellingShingle Review
Schalkamp, Ann-Kathrin
Rahman, Nabila
Monzón-Sandoval, Jimena
Sandor, Cynthia
Deep phenotyping for precision medicine in Parkinson's disease
title Deep phenotyping for precision medicine in Parkinson's disease
title_full Deep phenotyping for precision medicine in Parkinson's disease
title_fullStr Deep phenotyping for precision medicine in Parkinson's disease
title_full_unstemmed Deep phenotyping for precision medicine in Parkinson's disease
title_short Deep phenotyping for precision medicine in Parkinson's disease
title_sort deep phenotyping for precision medicine in parkinson's disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178512/
https://www.ncbi.nlm.nih.gov/pubmed/35647913
http://dx.doi.org/10.1242/dmm.049376
work_keys_str_mv AT schalkampannkathrin deepphenotypingforprecisionmedicineinparkinsonsdisease
AT rahmannabila deepphenotypingforprecisionmedicineinparkinsonsdisease
AT monzonsandovaljimena deepphenotypingforprecisionmedicineinparkinsonsdisease
AT sandorcynthia deepphenotypingforprecisionmedicineinparkinsonsdisease